Keryx Biopharmaceuticals said its experimental drug Zerenex achieved the primary goal of a Phase II trial involving chronic kidney disease patients with iron deficiency anemia and high serum phosphorus levels who are not on dialysis. The drug significantly reduced patients' serum phosphorus levels after 12 weeks of therapy compared with placebo and raised the percentage of iron available to make red blood cells. "The results show for the first time a significant benefit in both decreasing phosphate levels and a benefit in iron storage parameters and hemoglobin," analyst Reni Benjamin said.

Full Story:

Related Summaries